WEDNESDAY, July 2, 2025 (HealthDay News) — The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain formulations of amphetamine and methylphenidate, to warn about the medication’s risk for weight loss and other adverse reactions in patients younger than 6 years of age. Extended-release stimulants are […]
The post FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk first appeared on Physician’s Weekly.
